市場調査レポート

商品コード

1458405

血漿分画の世界市場：製品タイプ別、方法別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Plasma Fractionation Market Assessment, By Product Type, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年04月01日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 239 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の血漿分画の市場規模は、2024年～2031年の予測期間中に7.28%のCAGRで拡大し、2023年の302億5,000万米ドルから2031年には530億5,000万米ドルに成長すると予測されています。血漿分画市場は、血漿療法に対する需要の高まり、分画技術の進歩、血液関連疾患を持つ高齢化社会における標的疾患の発生増加などの要因の影響を受けて成長しています。血漿分画は、ヒト血漿から必要不可欠な治療薬を製造し、様々な医療ニーズに対応する上で重要な役割を果たしています。血漿療法の採用が増加し、さまざまな治療法や産業用途で血漿製品が利用されるようになったことで、血漿分画市場の需要が大幅に増加しています。また、市場を開拓して利益を得ようとする投資家の動きも、市場の成長をさらに後押ししています。しかし、血漿分画市場の主な抑制要因には、高コストと限られた償還、組み換え代替品による市場の混乱などがあります。さらに、厳しい規制要件は、新規企業の市場参入や既存企業の新製品市場投入を困難にする可能性があります。

希少疾患の増加と血漿に由来する治療への依存により、血漿療法はますます求められるようになり、この需要が世界の市場成長を後押ししています。PAHOのような組織は、特に献血が不十分な地域で信頼できる供給を維持するために、定期的かつ自発的な献血と血漿の提供を提唱しています。しかし、COVID-19の大流行により血漿提供が減少し、血漿を用いた治療に不可欠な材料が不足する結果となっています。血漿療法と血漿製品への需要の増加に伴い、血漿分画ソリューションの市場は今後大幅に上昇すると予想されます。

当レポートでは、世界の血漿分画市場について調査し、市場の概要とともに、製品タイプ別、方法別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 2.Global Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 3.Global Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 4.Global Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 5.Global Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 6.Global Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 7.Global Plasma Fractionation Market Share (%), By Region, 2017-2031F
Figure 8.North America Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 9.North America Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 10.North America Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 11.North America Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 12.North America Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 13.North America Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 14.North America Plasma Fractionation Market Share (%), By Country, 2017-2031F
Figure 15.United States Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 16.United States Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 17.United States Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 18.United States Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 19.United States Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 20.United States Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 21.Canada Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 22.Canada Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 23.Canada Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 24.Canada Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 25.Canada Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 26.Canada Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 27.Mexico Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 28.Mexico Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 29.Mexico Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 30.Mexico Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 31.Mexico Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 32.Mexico Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 34.Europe Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 35.Europe Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 36.Europe Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 37.Europe Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 38.Europe Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 39.Europe Plasma Fractionation Market Share (%), By Country, 2017-2031F
Figure 40.Germany Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 41.Germany Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 42.Germany Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 43.Germany Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 44.Germany Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 45.Germany Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 46.France Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 47.France Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 48.France Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 49.France Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 50.France Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 51.France Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 52.Italy Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 53.Italy Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 54.Italy Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 55.Italy Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 56.Italy Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 57.Italy Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 58.United Kingdom Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 59.United Kingdom Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 60.United Kingdom Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 61.United Kingdom Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 62.United Kingdom Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 63.United Kingdom Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 64.Russia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 65.Russia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 66.Russia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 67.Russia Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 68.Russia Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 69.Russia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 70.Netherlands Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 71.Netherlands Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 72.Netherlands Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 73.Netherlands Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 74.Netherlands Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 75.Netherlands Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 76.Spain Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 77.Spain Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 78.Spain Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 79.Spain Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 80.Spain Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 81.Spain Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 82.Turkey Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 83.Turkey Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 84.Turkey Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 85.Turkey Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 86.Turkey Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 87.Turkey Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 88.Poland Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 89.Poland Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 90.Poland Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 91.Poland Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 92.Poland Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 93.Poland Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 94.South America Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 95.South America Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 96.South America Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 97.South America Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 98.South America Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 99.South America Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 100.South America Plasma Fractionation Market Share (%), By Country, 2017-2031F
Figure 101.Brazil Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 102.Brazil Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 103.Brazil Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 104.Brazil Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 105.Brazil Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 106.Brazil Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 107.Argentina Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 108.Argentina Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 109.Argentina Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 110.Argentina Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 111.Argentina Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 112.Argentina Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 113.Asia-Pacific Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 114.Asia-Pacific Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 115.Asia-Pacific Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 116.Asia-Pacific Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 117.Asia-Pacific Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 118.Asia-Pacific Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 119.Asia-Pacific Plasma Fractionation Market Share (%), By Country, 2017-2031F
Figure 120.India Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 121.India Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 122.India Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 123.India Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 124.India Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 125.India Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 126.China Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 127.China Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 128.China Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 129.China Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 130.China Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 131.China Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 132.Japan Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 133.Japan Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 134.Japan Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 135.Japan Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 136.Japan Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 137.Japan Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 138.Australia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 139.Australia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 140.Australia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 141.Australia Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 142.Australia Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 143.Australia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 144.Vietnam Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 145.Vietnam Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 146.Vietnam Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 147.Vietnam Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 148.Vietnam Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 149.Vietnam Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 150.South Korea Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 151.South Korea Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 152.South Korea Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 153.South Korea Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 154.South Korea Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 155.South Korea Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 156.Indonesia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 157.Indonesia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 158.Indonesia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 159.Indonesia Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 160.Indonesia Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 161.Indonesia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 162.Philippines Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 163.Philippines Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 164.Philippines Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 165.Philippines Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 166.Philippines Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 167.Philippines Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 168.Middle East & Africa Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 169.Middle East & Africa Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 170.Middle East & Africa Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 171.Middle East & Africa Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 172.Middle East & Africa Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 173.Middle East & Africa Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 174.Middle East & Africa Plasma Fractionation Market Share (%), By Country, 2017-2031F
Figure 175.Saudi Arabia Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 176.Saudi Arabia Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 177.Saudi Arabia Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 178.Saudi Arabia Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 179.Saudi Arabia Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 180.Saudi Arabia Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 181.UAE Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 182.UAE Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 183.UAE Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 184.UAE Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 185.UAE Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 186.UAE Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 187.South Africa Plasma Fractionation Market, By Value, In USD Billion, 2017-2031F
Figure 188.South Africa Plasma Fractionation Market, By Volume, In Million Units, 2017-2031F
Figure 189.South Africa Plasma Fractionation Market Share (%), By Product Type, 2017-2031F
Figure 190.South Africa Plasma Fractionation Market Share (%), By Method, 2017-2031F
Figure 191.South Africa Plasma Fractionation Market Share (%), By Application, 2017-2031F
Figure 192.South Africa Plasma Fractionation Market Share (%), By End-user, 2017-2031F
Figure 193.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194.By Method Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11202

Global plasma fractionation market is projected to witness a CAGR of 7.28% during the forecast period 2024-2031, growing from USD 30.25 billion in 2023 to USD 53.05 billion in 2031. The plasma fractionation market is thriving under the influence of factors, including the rising demand for blood plasma therapies, advancements in fractionation technologies, and the growing occurrence of target diseases among an aging population with blood-related diseases. Plasma fractionation plays a crucial role in producing essential therapeutics from human plasma, addressing various medical needs. The growing adoption of plasma therapies and utilization of plasma products in various therapeutics and industrial applications significantly increases the demand in the plasma fractionation market. Alongside, the investors' traction to develop the market and derive profit out of it, further enhances the market growth. However, the main restraints for the plasma fractionation market include high costs and limited reimbursements, as well as market disruption caused by recombinant alternatives. Additionally, stringent regulatory requirements can make it difficult for new companies to enter the market and for existing companies to bring new products to market.

In November 2023, Grifols, a respected plasma medicine company, gained FDA approval for its expanded manufacturing site in Clayton. This approval covers the production of Gamunex-C, a prominent Grifols immunoglobulin (Ig) brand. With the new facility, Grifols can now produce 16 million grams of Gamunex-C annually, boosting its global capacity to 60 million grams. Grifols is also planning to secure FDA approval to produce XEMBIFY, its rapidly growing subcutaneous Ig, at the same facility.

Rising Demand for Blood Plasma Therapies

Plasma therapy is becoming increasingly sought-after due to the growing number of rare diseases and reliance on treatments derived from blood plasma. This demand is boosting market growth worldwide. Organizations like PAHO advocate for regular and voluntary blood and plasma donations to maintain a reliable supply, particularly in areas where donations are insufficient. However, the COVID-19 pandemic reduced plasma donations, resulting in a shortage of essential materials for plasma-based treatments. With the increasing demand for plasma therapies and plasma products, the market for plasma fractionation solutions is anticipated to rise significantly in the upcoming future. Manufacturers like Takeda are dedicated to developing manufacturing setups to cater to the growing requirements of the market.

In April 2023, Takeda, a leading Japanese biopharmaceutical company, plans to construct Japan's largest facility for producing plasma-based medicines (PDTs) in Osaka. This investment aims to meet the growing demand for PDTs domestically and globally. The new facility will significantly increase Takeda's plasma manufacturing capacity in Japan by approximately five times. With an estimated investment of JPY 100 billion, construction will commence in early 2024, and the facility is expected to be operational by 2030, bolstering Takeda's global manufacturing network.

Growing Prevalence of Immunodeficiency Diseases

The growing prevalence of immunodeficiency diseases is driving the demand for plasma fractionation due to the effectiveness of plasma-derived therapies in treating these conditions. Plasma-derived therapies have become essential treatment options for rare diseases and immunodeficiency disorders, leading to a surge in demand for these therapies. Plasma fractionation involves separating and purifying key blood plasma components like immunoglobulins, albumins, and anticoagulant factors, which are crucial for formulating life-saving therapeutics. Primary immunodeficiency diseases affect an estimated 60 lakh people worldwide, and 70% to 90% of individuals have undiagnosed primary immunodeficiency conditions. As per an estimation, about 5,000 individuals within the United Kingdom suffer from primary immunodeficiency disorder. Approximately 50.5 people out of every 1,00,000 in the United States are estimated to have a primary immunodeficiency disorder.

Immunoglobulins Segment to be Fastest Growing

Immunoglobulins are popular for plasma fractionation due to their use in treating individuals with antibody deficiencies. Immunoglobulin replacement therapy is the standard treatment for these patients, and it involves the administration of intravenous immunoglobulin (IVIG) or subcutaneously (SCIG). Immunoglobulin is used to help patients suffering from primary and secondary immunodeficiency disorders and combat viral and bacterial infections. Several products related to this segment are under clinical investigation and seem to grow with time. For instance, in July 2023, the FDA approved the updated application for GC5107B, an immune globulin solution intended for intravenous use in patients who have a weakened immune system known as primary humoral immunodeficiency. This liquid solution contains human immunoglobulin G (100mg/mL) and is extracted from donated human plasma in the United States. The application is supported by a study that observed the effectiveness and safety of GC5107B with 49 patients between the ages of 3 and 70 with confirmed primary immunodeficiency.

Centrifugation to be Leading Method Type

Centrifugation is a widely used method for plasma fractionation due to its effectiveness in separating individual plasma proteins based on their density. The process involves using centrifuges and centrifugal force to segregate plasma proteins, with precipitated proteins of higher density remaining in the centrifuge, while lighter components are forced out. This method has seen increased application over the years, leading to the development of specialized centrifuges for large-scale plasma processing. In industrial settings, vertical centrifuge plasma fractionation systems are designed specifically for pharmaceutical applications to separate different plasma fractions efficiently. These systems ensure optimal yield of valuable raw materials with maximum purity and quality, meeting the stringent requirements of reliable processes in medical applications.

North America to be the Dominating Region

North America's leadership in the plasma fractionation market stems from several key reasons. Most plasma supplies for manufacturing plasma-derived medicinal products come from North American countries, with the United States commercial plasma industry historically dominating international supply. The United States plays a crucial role in meeting international needs for plasma due to its significant export of plasma-derived products. The United States supplies around 70% of the world's plasma. The strong presence of market players in North America strengthens the lead of the region in plasma fractionation market. In April 2023, CSL Plasma, a subsidiary of CSL Behring, opened a new plasma collection center in Kankakee, Illinois. This marks their 320th center in the U.S. Located near the CSL Behring manufacturing site, this center collects plasma used to create life-saving therapies for rare and severe diseases, such as immune disorders, swelling, respiratory diseases, and bleeding or neurological conditions.

Future Market Scenario (2024 - 2031F)

Future trends in plasma-derived therapies include a focus on reducing fractionation scale, adopting new technologies, and increasing automation to improve efficiency and reduce costs. The plasma industry is exploring novel manufacturing technologies, such as flammable material-free fractionation and continuous manufacturing, to improve the efficiency of fractionation facilities. Additionally, there is a growing demand for plasma-derived therapies due to an aging population, clinical successes, and recent applications for both widespread diseases and many rare conditions. Apart from this, an increase in the number of plasma collection centers is also strengthening the plasma fractionation market. For instance, in November 2023, ADMA Biologics, a biopharmaceutical company specializing in plasma-derived biologics, has secured FDA approval for its newest plasma collection center in Laurel, Maryland. This facility began operations earlier this year and has already started collecting plasma. With this approval, ADMA can now distribute the collected plasma in the U.S. for further processing into biological products.

Key Players Landscape and Outlook

Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin Innovation B.V., and Bio Products Laboratory Ltd. are some of the key players in the plasma fractionation market. These companies are actively involved in research and development initiatives to launch new plasma-derived therapies and are focusing on acquiring new plasma collection centers to streamline their operations, along with expanding their manufacturing facilities.

In December 2023, GC Biopharma, a South Korean biotech firm, commenced construction on a plasma fractionation plant in Indonesia's Jababeka Industrial Estate. This plant will be the first of its kind in the country. The project was approved by the Indonesian government in June, and construction is underway after just six months of progress. The project is supported by the government's commitment to advancing healthcare.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Plasma Fractionation Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2.By Product Type
- 4.2.1.Albumin
- 4.2.2.Immunoglobulins
  - 4.2.2.1.Intravenous immunoglobulins
  - 4.2.2.2.Subcutaneous immunoglobulins
  - 4.2.2.3.Others
- 4.2.3.Coagulation Factors
  - 4.2.3.1.Factor VIII
  - 4.2.3.2.Factor IX
  - 4.2.3.3.Von Willebrand Factor
  - 4.2.3.4.Prothrombin Complex Concentrates
  - 4.2.3.5.Fibrinogen Concentrates
  - 4.2.3.6.Others
- 4.2.4.Protease Inhibitors
- 4.2.5.Others
4.3.By Method
- 4.3.1.Centrifugation
- 4.3.2.Depth Filtration
- 4.3.3.Chromatography
- 4.3.4.Others
4.4.By Application
- 4.4.1.Neurology
- 4.4.2.Hematology
- 4.4.3.Oncology
- 4.4.4.Immunology
- 4.4.5.Pulmonology
- 4.4.6.Others
4.5.By End-user
- 4.5.1.Hospitals & Clinics
- 4.5.2.Clinical Research
- 4.5.3.Others
4.6.By Region
- 4.6.1.North America
- 4.6.2.Europe
- 4.6.3.Asia-Pacific
- 4.6.4.South America
- 4.6.5.Middle East and Africa
4.7.By Company Market Share (%), 2023

5.Global Plasma Fractionation Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Product Type
  - 5.1.2.1.Albumin
  - 5.1.2.2.Immunoglobulins
  - 5.1.2.2.1.Intravenous immunoglobulins
  - 5.1.2.2.2.Subcutaneous immunoglobulins
  - 5.1.2.2.3.Others
  - 5.1.2.3.Coagulation Factors
  - 5.1.2.3.1.Factor VIII
  - 5.1.2.3.2.Factor IX
  - 5.1.2.3.3.Von Willebrand Factor
  - 5.1.2.3.4.Prothrombin Complex Concentrates
  - 5.1.2.3.5.Fibrinogen Concentrates
  - 5.1.2.3.6.Others
  - 5.1.2.4.Protease Inhibitors
  - 5.1.2.5.Others
- 5.1.3.By Method
  - 5.1.3.1.Centrifugation
  - 5.1.3.2.Depth Filtration
  - 5.1.3.3.Chromatography
  - 5.1.3.4.Others
- 5.1.4.By Application
  - 5.1.4.1.Neurology
  - 5.1.4.2.Hematology
  - 5.1.4.3.Oncology
  - 5.1.4.4.Immunology
  - 5.1.4.5.Pulmonology
  - 5.1.4.6.Others
- 5.1.5.By End-user
  - 5.1.5.1.Hospitals & Clinics
  - 5.1.5.2.Clinical Research
  - 5.1.5.3.Others
- 5.1.6.United States*
  - 5.1.6.1.Market Size & Forecast
  - 5.1.6.1.1.By Value
  - 5.1.6.1.2.By Volume
  - 5.1.6.2.By Product Type
  - 5.1.6.2.1.Albumin
  - 5.1.6.2.2.Immunoglobulins
  - 5.1.6.2.2.1.Intravenous immunoglobulins
  - 5.1.6.2.2.2.Subcutaneous immunoglobulins
  - 5.1.6.2.2.3.Others
  - 5.1.6.2.3.Coagulation Factors
  - 5.1.6.2.3.1.Factor VIII
  - 5.1.6.2.3.2.Factor IX
  - 5.1.6.2.3.3.Von Willebrand Factor
  - 5.1.6.2.3.4.Prothrombin Complex Concentrates
  - 5.1.6.2.3.5.Fibrinogen Concentrates
  - 5.1.6.2.3.6.Others
  - 5.1.6.2.4.Protease Inhibitors
  - 5.1.6.2.5.Others
  - 5.1.6.3.By Method
  - 5.1.6.3.1.Centrifugation
  - 5.1.6.3.2.Depth Filtration
  - 5.1.6.3.3.Chromatography
  - 5.1.6.3.4.Others
  - 5.1.6.4.By Application
  - 5.1.6.4.1.Neurology
  - 5.1.6.4.2.Hematology
  - 5.1.6.4.3.Oncology
  - 5.1.6.4.4.Immunology
  - 5.1.6.4.5.Pulmonology
  - 5.1.6.4.6.Others
  - 5.1.6.5.By End-user
  - 5.1.6.5.1.Hospitals & Clinics
  - 5.1.6.5.2.Clinical Research
  - 5.1.6.5.3.Others
- 5.1.7.Canada
- 5.1.8.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Product Type
6.2.By Method
6.3.By Application
6.4.By End-user
6.5.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Patent Landscape
9.2.Regulatory Approvals
9.3.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Grifols S.A.
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.CSL Limited
13.3.Takeda Pharmaceutical Company Limited
13.4.Octapharma AG
13.5.Kedrion S.p.A
13.6.LFB S.A.
13.7.Biotest AG
13.8.Sanquin Innovation B.V.
13.9.Bio Products Laboratory Ltd.
13.10.Intas Pharmaceuticals Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

血漿分画の世界市場：製品タイプ別、方法別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Plasma Fractionation Market Assessment, By Product Type, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の血漿分画市場の見通し、2017年～2031年

第5章世界の血漿分画市場の見通し、地域別、2017年～2031年

第6章 2023年の市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Plasma Fractionation Market Outlook, 2017-2031F

5.Global Plasma Fractionation Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

血漿分画の世界市場：製品タイプ別、方法別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Plasma Fractionation Market Assessment, By Product Type, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の血漿分画市場の見通し、2017年～2031年

第5章 世界の血漿分画市場の見通し、地域別、2017年～2031年

第6章 2023年の市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要参入企業の見通し

第14章 戦略的提言

第15章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Plasma Fractionation Market Outlook, 2017-2031F

5.Global Plasma Fractionation Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の血漿分画市場の見通し、2017年～2031年

第5章世界の血漿分画市場の見通し、地域別、2017年～2031年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項